AU2020402717A1 - Compounds for treating familial dysautonomia - Google Patents

Compounds for treating familial dysautonomia Download PDF

Info

Publication number
AU2020402717A1
AU2020402717A1 AU2020402717A AU2020402717A AU2020402717A1 AU 2020402717 A1 AU2020402717 A1 AU 2020402717A1 AU 2020402717 A AU2020402717 A AU 2020402717A AU 2020402717 A AU2020402717 A AU 2020402717A AU 2020402717 A1 AU2020402717 A1 AU 2020402717A1
Authority
AU
Australia
Prior art keywords
methyl
pyrimidin
chloro
amine
thieno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020402717A
Other languages
English (en)
Inventor
Michael A. Arnold
Amal DAKKA
Gary Mitchell Karp
Tom Tuan LUONG
Christie Morrill
Jana Narasimhan
Nikolai A. Naryshkin
Anthony Turpoff
Jiashi WANG
Nanjing Zhang
Xiaoyan Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics Inc
Original Assignee
PTC Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PTC Therapeutics Inc filed Critical PTC Therapeutics Inc
Publication of AU2020402717A1 publication Critical patent/AU2020402717A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
AU2020402717A 2019-12-12 2020-12-07 Compounds for treating familial dysautonomia Abandoned AU2020402717A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962947049P 2019-12-12 2019-12-12
US62/947,049 2019-12-12
PCT/US2020/063612 WO2021118929A1 (en) 2019-12-12 2020-12-07 Compounds for treating familial dysautonomia

Publications (1)

Publication Number Publication Date
AU2020402717A1 true AU2020402717A1 (en) 2022-06-23

Family

ID=74046197

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020402717A Abandoned AU2020402717A1 (en) 2019-12-12 2020-12-07 Compounds for treating familial dysautonomia

Country Status (14)

Country Link
US (1) US20230057568A1 (https=)
EP (1) EP4072677A1 (https=)
JP (2) JP2023506488A (https=)
KR (1) KR20220113700A (https=)
CN (1) CN115209955A (https=)
AU (1) AU2020402717A1 (https=)
BR (1) BR112022011364A2 (https=)
CA (1) CA3160053A1 (https=)
CL (1) CL2022001523A1 (https=)
CO (1) CO2022008195A2 (https=)
IL (1) IL293764A (https=)
MX (1) MX2022007094A (https=)
PE (1) PE20221581A1 (https=)
WO (1) WO2021118929A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108519TA (en) 2019-02-13 2021-09-29 Ptc Therapeutics Inc Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
MX2024002887A (es) * 2021-09-07 2024-05-28 Ptc Therapeutics Inc Metodos para tratar enfermedades neurodegenerativas.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1028964A1 (en) * 1997-11-11 2000-08-23 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
WO2005007083A2 (en) * 2003-06-18 2005-01-27 Smithkline Beecham Corporation Chemical compounds
JP2009007341A (ja) * 2007-06-01 2009-01-15 Mitsubishi Tanabe Pharma Corp 医薬組成物
EP2014663A1 (de) * 2007-07-12 2009-01-14 Bayer Schering Pharma AG Thienopyrimidylamine als Modulatoren des EP2-Rezeptors
EP2611812A1 (en) * 2010-09-01 2013-07-10 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
CN103242341B (zh) * 2013-04-19 2015-12-09 中国科学院广州生物医药与健康研究院 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用
CA2973949C (en) * 2015-01-16 2023-07-11 The General Hospital Corporation Compounds for improving mrna splicing
GB201700814D0 (en) * 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
WO2018151326A1 (ja) * 2017-02-20 2018-08-23 国立大学法人京都大学 スプライシング異常に起因する遺伝性疾病のための医薬組成物及び治療方法
SG11202108519TA (en) * 2019-02-13 2021-09-29 Ptc Therapeutics Inc Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) * 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia

Also Published As

Publication number Publication date
BR112022011364A2 (pt) 2022-08-23
WO2021118929A1 (en) 2021-06-17
KR20220113700A (ko) 2022-08-16
JP2025133750A (ja) 2025-09-11
CO2022008195A2 (es) 2022-07-29
CL2022001523A1 (es) 2023-03-31
US20230057568A1 (en) 2023-02-23
JP2023506488A (ja) 2023-02-16
CA3160053A1 (en) 2021-06-17
PE20221581A1 (es) 2022-10-06
MX2022007094A (es) 2022-07-11
IL293764A (en) 2022-08-01
CN115209955A (zh) 2022-10-18
EP4072677A1 (en) 2022-10-19

Similar Documents

Publication Publication Date Title
KR102907028B1 (ko) 가족성 자율신경실조증 치료를 위한 티오에노[3,2-b]피리딘-7-아민 화합물
KR20250035623A (ko) 척추소뇌성 운동실조증 유형 3을 치료하기 위한 화합물
US12398140B2 (en) Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia
JP2025133750A (ja) 家族性自律神経失調症を処置するための化合物
EP4288059A1 (en) Compounds for treating spinocerebellar ataxia type 3
WO2023039370A1 (en) Methods for treating neurogenerative diseases
AU2020361735B2 (en) 2-azaspiro(3.4)octane derivatives as M4 agonists
CN119390705A (zh) 作为m4激动剂的5-氧杂-2-氮杂螺[3.4]辛烷衍生物
BR122024013729A2 (pt) Compostos de tieno[3,2-b]piridin-7-amina, seus usos no tratamento de disautonomia familiar e composição farmacêutica compreendendo os mesmos
US20260001889A1 (en) Compositions useful for modulating splicing

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period